Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Krystle A. Lang Kuhs, Michael Pawlita, Sandra P. Gibson, Nicole Schmitt, Sumita Trivedi, Athanassios Argiris, Aimée R. Kreimer, Robert L. Ferris, Tim Waterboer

Research output: Contribution to journalArticle

Abstract

Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalCancer Epidemiology
Volume42
DOIs
StatePublished - Jun 1 2016

    Fingerprint

Keywords

  • HPV antibodies
  • HPV seropositivity
  • HPV16
  • HPV16 E6
  • Human papillomavirus 16
  • Non-OPC
  • Non-oropharyngeal cancer
  • OPC
  • Oropharyngeal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology

Cite this

Lang Kuhs, K. A., Pawlita, M., Gibson, S. P., Schmitt, N., Trivedi, S., Argiris, A., Kreimer, A. R., Ferris, R. L., & Waterboer, T. (2016). Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiology, 42, 46-52. https://doi.org/10.1016/j.canep.2016.03.003